Replies to post #110596 on Biotech Values

[ghmm]

The outlook for Danoprevir may have dimmed especially given Roche's cuts a little while back but please keep in mind what the title of the event was "Late-stage pipeline event"
also there are several studies active so I wouldn't go all out betting Roche partners for another PI with one of your HCV holdings just yet.

http://clinicaltrials.gov/ct2/show/NCT01185860
http://clinicaltrials.gov/ct2/show/NCT01220947
http://clinicaltrials.gov/ct2/show/NCT01185873

If Roche continues with these studies I think the data produced and perhaps more so the competitive HCV landscape at the time will determine the future of the molecule.